Nishizono 1994.
Methods | Randomisation: randomised, no further details. Allocation: procedure not described. Blinding: n.i., probably open. Duration: 4 weeks. Design: n.i., Location: multicentre. Setting: n.i., | |
Participants | Diagnosis: schizophrenia (ICD‐10). N = 109. Gender: n.i., Age: n.i., History: duration stable ‐ n.i., duration ill ‐ n.i., number of previous hospitalisations ‐ n.i., age at onset ‐ n.i., severity of illness ‐ n.i., baseline antipsychotic dose ‐ n.i., |
|
Interventions | 1. Haloperidol: flexible dose, allowed dose range n.i., dose max. 21 mg/day. N = 57. 2. Chlorpromazine: flexible dose, allowed dose range n.i., dose max. 450 mg/day. N = 52. Other medication: n.i.. | |
Outcomes | Response to treatment: at least 50% reduction in BPRS total score. Unable to use: Mental state: BPRS (incomplete data, no SD). Global state: Global Assessment Scale (incomplete data, no SD). Leaving the study early (no data available). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Randomised, no further details. |
Allocation concealment (selection bias) | Unclear risk | Procedure not described. |
Blinding of participants and personnel (performance bias) All outcomes | High risk | n.i., probably open. |
Blinding of outcome assessment (detection bias) All outcomes | High risk | n.i., probably open. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Not enough information to permit judgement about incomplete outcome data. |
Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement about selective reporting. |
Other bias | Unclear risk | Insufficient information about other sources of bias. |